Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by davgroon Dec 05, 2022 3:34pm

131 Views

Post# 35151807

Stockhouse Admins Doing an Excellent Job Monitoring Content

Duster340 - (12/5/2022 2:05:25 PM) wrote: i am sure you already reported my post here. they won't take it down as it does not break any rules.

Wrong again. Another of your posts removed that violated content rules. What is that four (4) removed just since November 28th ? I am sure you are drawing a lot of attention from the SH Admins. You may want to read the Stockhouse System Update Announcement in more detail. I have provided you with the link below:

https://stockhouse.com/announcements/2022-11-28/new-community-management-in-effect

<< Previous

Bullboard Posts

Next >>

NervGen: Are amazing human trial results leaking out?